MDRNA (NASDAQ: [[ticker:MRNA]]), the Bothell, WA-based developer of RNA interference therapies, said today it has formed a research agreement with Pfizer. MDRNA will be responsible for taking oligonucleotides from Pfizer, and formulating them in amino acid packages that MDRNA has developed for RNA interference. The smaller company will also be asked to design and synthesize RNAi drugs against targets chosen by Pfizer. Financial terms of the deal weren’t disclosed.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
